Quick Dispatch:
Your surpass cvot tirzepatide results Diabetes Dialogue: Tirzepatide and SURPASS-CVOT Topline Results orders ship within 1-2 business days.
Delivery Options:
Order Tracking:
You'll receive a tracking link by email once your surpass cvot tirzepatide results Diabetes Dialogue: Tirzepatide and SURPASS-CVOT Topline Results ships.
Need Help?
Questions about surpass cvot tirzepatide results Diabetes Dialogue: Tirzepatide and SURPASS-CVOT Topline Results, sizing, or delivery? We're just an email away.
Live Shipping Estimates:
Enter your location at checkout to see available shipping methods and costs for surpass cvot tirzepatide results Diabetes Dialogue: Tirzepatide and SURPASS-CVOT Topline Results in your area.
What do topline data from SURPASS-CVOT tell us about the potential of tirzepatide? , Check out the latest #DiabetesDialogue to hear from @DIanaMIsaacs and @Natalie_Bellini about the
27.88
In the SURPASS-CVOT head-to-head trial involving over 13,000 adults with T2D and ASCVD, tirzepatide (Mounjaro) matched dulaglutide in reducing major cardiovascular events (8% lower risk) and significantly cut all-cause mortality by 16%
26.10
Media Centre
26.66
Diabetes Distilled: SURPASS-CVOT – Tirzepatide demonstrates cardiovascular benefit in secondary prevention
24.19
In patients with type 2 diabetes and atherosclerotic cardiovascular disease, tirzepatide was noninferior to dulaglutide with respect to major cardiovascular events. Read the full SURPASS-CVOT trial
27.66
Tirzepatide in SURPASS‑CVOT: Favorable Cardiovascular Outcomes in Type 2 Diabetes
29.64
02188-7/asset/2a04fe44-9b50-44db-92c6-1be9af993976/main.assets/gr2_lrg.jpg "Tirzepatide versus insulin glargine in type 2 diabetes and increased cardiovascular risk (SURPASS-4): a randomised, open-label, parallel-group, multicentre, phase 3 trial")
Tirzepatide versus insulin glargine in type 2 diabetes and increased cardiovascular risk (SURPASS-4): a randomised, open-label, parallel-group, multicentre, phase 3 trial
29.05
